New Paradigm of COVID-19 with Pulmonary Tuberculosis: A Brief Review
##plugins.themes.bootstrap3.article.main##
The global threat of respiratory infectious diseases is constantly evolving among the world population. Severe acute respiratory syndrome coronavirus 2 is a novel member of the respiratory virus causing the coronavirus disease 2019 (COVID-19), an emerging disease characterized with pneumonia-like symptoms. Since it has been established as a worldwide pandemic, the cases of coronavirus infection are still growing and remain a global health concern. Meanwhile, tuberculosis also remains a great contributor to chronic respiratory communicable disease with cases still developing relentlessly. In a person manifested with chronic tuberculosis, co-infection of COVID-19 may occur and causes more severe clinical manifestations than tuberculosis single infection. On the other hand, it is also possible for people who have COVID-19 to be infected with new tuberculosis infection, especially if the individual lives in a developing country that tends to be tuberculosis endemic. Therefore, these two respiratory infections have become a worldwide double burden. This review provides a comprehensive overview of the new paradigm regarding these two worldwide emerging infectious diseases to provide a good understanding of their clinical aspects and to achieve the best possible future outcomes.
Downloads
References
-
R. Lu, X. Zhao, J. Li, et al., “Genomic characterization and epidemiology of 2019 novel coronavirus: implication for virus origins and receptor binding,” Lancet, vol. 395, no. 10224, pp. 565-574, Feb 2020.
DOI | Google Scholar
1
-
World Health Organization (2020). Coronavirus disease (COVID-19) Pandemic – Emergency Use Listing Procedure (EUL) open for in vitro diagnostics [Online]. Available from: https://www.who.int/diagnostics _laboratory.
Google Scholar
2
-
C. Sohrabi, Z. Alsafi, N. O'Neill, et al., “World Health Organization declares global emergency: A review of the 2019 novel Coronavirus (COVID-19),” Int J Surg., vol. 76, pp. 71-76, 2020.
DOI | Google Scholar
3
-
Kemenkes RI, “Coronavirus disease 2019,” Peraturan Menteri Kesehatan Republik Indonesia, no. 9, pp. 2-6, 2020.
Google Scholar
4
-
R.R. Nathavitharana, J.S. Friedland, “A tale of two global emergencies: tuberculosis control efforts can learn from the Ebola outbreak,” Eur Respi J., vol. 46, pp. 293-296, 2015.
DOI | Google Scholar
5
-
S. Yadav, G. Rawal, “The case of pulmonary tuberculosis with COVID-19 in an Indian male: a first of its type case ever reported from South Asia,” PAMJ, vol. 36, no. 374, pp. 1-5, 2020.
DOI | Google Scholar
6
-
World Health Organization (2019). Global Tuberculosis Report 2019 [Online]. Available from: https://apps.who.int/iris/bitstream/handle/
Google Scholar
7
-
Depkes RI, “Infodatin Tuberkulosis,” Kementerian Kesehatan RI, pp. 1-10, 2018.
Google Scholar
8
-
World Health Organization, “Information Note Tuberculosis and COVID-19: Considerations for Tuberculosis (TB) care,” World Health Organization, pp. 1-10, 2020.
Google Scholar
9
-
Z. Yao, J. Chen, Q. Wang, et al., “Three patients with COVID-19 and pulmonary tuberculosis, Wuhan, China, January-February 2020,” Emerging Infectious Diseases, vol. 26, no. 11, pp. 2754-2757, 2020.
DOI | Google Scholar
10
-
K.N. Pravin, E. Chourasia, “Use of GeneXpert assay for diagnosis of tuberculosis from body fluid specimens, a 2 years stud,” J Microbiol Biotechnol., vol. 1, no. 1, pp. 000105, 2016.
DOI | Google Scholar
11
-
A.S. Piatek, M. van Cleeff, H. Alexander, et al., “GeneXpert for TB diagnosis: planned and purposeful implementation,” Glob Health Sci Pract., vol. 1, no. 1, pp. 18-23, 2013.
DOI | Google Scholar
12
-
B.A. al Ubaidi, “The radiological diagnosis of pulmonary tuberculosis (TB) in primary care,” J Fam Med Dis Prev., vol. 4, no. 1, pp. 1-7, 2018.
DOI | Google Scholar
13
-
Z.A. Memish, J.A. Al-Tawfi, A. Assiri, et al., “Middle East respiratory syndrome coronavirus disease in children,” Pediatr Inf Dis J., vol. 33, pp. 904-906, 2014.
DOI | Google Scholar
14
-
D. Wang, B. Hu, C. Hu, et al., “Clinical characteristics of 138 hospitalized patients with 2019 novel Coronavirus-infected pneumonia in Wuhan, China,” JAMA vol. 323, pp. 1061-1069, 2020.
DOI | Google Scholar
15
-
E.J. Walter, S. Hanna-Jumma, M. Carraretto, et al., “The pathophysiological basis and consequences of fever,” Crit Care, vol. 20, pp. 200, 2016.
DOI | Google Scholar
16
-
D.E. Gordon, G.M. Jang, M. Bouhaddou, et al., “A SARS-CoV-2 protein interaction map reveals targets for drug repurposing,” Nature, pp. 459-468, 2020.
Google Scholar
17
-
M.Z. Tay, C.M. Poh, L. Rénia L, et al., “The trinity of COVID-19: Immunity, inflammation and intervention,” Nat Rev Immunol., vol. 20, no. 6, pp. 363-374, 2020.
DOI | Google Scholar
18
-
B. Diao, C. Wang, Y. Tan, et al., “Reduction and functional exhaustion of T cells in patients with Coronavirus Disease 2019 (COVID-19),” Front Immunol., vol. 11, pp. 827, 2020.
DOI | Google Scholar
19
-
W. Liu, A. Fontanet, P. Zhang, et al., “Pulmonary tuberculosis and SARS, China,” Emerge Infect Dis., vol. 12, pp. 707-709, 2006.
DOI | Google Scholar
20
-
J.G. Low, C.C. Lee, Y.S. Leo YS, et al., “Severe acute respiratory syndrome and pulmonary tuberculosis,” Clin Infect Dis., vol. 38, pp. e123-125, 2004.
DOI | Google Scholar
21
-
F. Pan, T. Ye, P. Sun, et al., “Time course of lung changes on chest CT during recovery from 2019 novel coronavirus (COVID-19) pneumonia,” Radiology, vol. 295, no. 3, pp. 715-721, 2020.
DOI | Google Scholar
22
-
F. Faqihi, A. Alharthy, A. Noor, et al., “COVID-19 in a patient with active tuberculosis: a rare case-report,” Respiratory Medicine Case Reports, vol. 31, pp. 101146, 2020.
DOI | Google Scholar
23
-
L. Cardinale, D. Parlatano, F. Boccuzzi, et al., “The imaging spectrum of pulmonary tuberculosis,” Acta Radiol, vol. 56, pp. 557-564, 2015.
DOI | Google Scholar
24
-
J. Burrill, C.J. Williams, G. Bain, et al., “Tuberculosis: A radiologic review,” RadioGraphics, vol. 27, pp. 1255-1273, 2007.
DOI | Google Scholar
25
-
Z. Yousaf, A.A. Khan, H.A. Chaudhary, et al., “Cavitary pulmonary tuberculosis with COVID-19 coinfection,” ID Cases, pp. 1-3, 2020.
DOI | Google Scholar
26
-
Centers for Disease Control and Prevention (2020). Tuberculosis [Online]. Available at https://www.who.int/news-room/fact-sheets/ detail/tuberculosis.
Google Scholar
27
-
F. Abay, A. Yalew, A. Shibabaw, et al., “Hematological abnormalities of pulmonary tuberculosis patients with and without HIV at the University of Gondar Hospital, Northwest Ethiopia: a comparative cross-sectional study,” Tuberc Res Treat, pp. 5740951, 2018.
DOI | Google Scholar
28
-
P.R. Sharma, S. Jain, R.N. Bamezai et al., “Utility of serum LDH isoforms in the assessment of mycobacterium tuberculosis induced pathology in TB patients of Sahariya tribe,” Indian J Clin Biochem., vol. 25, pp. 57-63, 2010.
DOI | Google Scholar
29
-
A.J. Rodriguez-Morales, J.A. Cardona-Ospina, E. Gutiérrez-Ocampo, et al., “Clinical, laboratory and imaging features of COVID-19: a systematic review and meta-analysis,” Travel Med Infect Dis, vol. 34, pp. 101623, 2020.
DOI | Google Scholar
30
-
Y. Liu, L. Bi, Y. Chen, et al. (2020). Active or latent tuberculosis increases susceptibility to COVID-19 and disease severity. Infectious Diseases [Online] Available from: http: //medrxiv.org/.
Google Scholar
31
-
World Health Organization (2020). Summaries of Evidence Experimental Therapeutics [Online]. Available from: https://www. who.int/ebola/drc-2018/.
Google Scholar
32
-
M. Tadolini, L.R. Codecasa, J.M. García, “Active tuberculosis, sequelae and COVID-19 co-infection: first cohort of 49 cases,” Eur Respir J., vol. 56, pp. 2001398, 2020.
DOI | Google Scholar
33
-
T. Togun, B. Kampmann, N.G. Stoker, et al., “Anticipating the impact of the COVID-19 pandemic on TB patients and TB control programmes,” Ann Clin Microbiol Antimicrobe, vol. 19, pp. 1-6, 2020.
DOI | Google Scholar
34
-
D. Raoult, A. Zumla, F. Locatelli et al., “Coronavirus infections: epidemiological, clinical and immunological features and hypotheses,” Cell Stress, vol. 4, no. 4, pp. 66-75, 2020.
DOI | Google Scholar
35
-
L. Di, Y. Li, “The risk factor of false-negative and false positive for T-SPOT.TB in active tuberculosis,” Journal of Clinical Laboratory Analysis, vol. 32, no. 2, pp. e22273, 2018.
DOI | Google Scholar
36
-
Y.S. Kwon, Y.H. Kim, K. Jeon, “Factors that predict negative results of quantiferon-TB gold in-tube test in patients with culture-confirmed tuberculosis: a multicenter retrospective cohort study,” PLoS One, vol. 10, no. 6, pp. e0129792, 2015.
DOI | Google Scholar
37
-
W. Zhang, Y. Zhao, F. Zhang, “The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): the perspectives of clinical immunologists from China,” Clinical Immunology, vol. 214, pp. 108393, 2020.
DOI | Google Scholar
38
-
J.M. Sanders, M.L. Monogue, T.Z. Jodlowski, et al., “Pharmacologic treatments for Coronavirus disease 2019 (COVID-19): a review,” JAMA vol. 323, no. 18, pp. 1824-1836, 2020.
DOI | Google Scholar
39
-
H. Jamshaid, F. Zahid, U.I. Din et al., “Diagnostic and treatment strategies for COVID-19,” AAPS Pharma Sci Tech., vol. 21, no. 222, pp. 1-14, 2020.
DOI | Google Scholar
40
-
L.J. Ho, S.F. Luo, J.H. Lai, “Biological effects of interleukin-6: clinical applications in autoimmune diseases and cancers,” Biochem Pharmacol., vol. 97, no. 1, pp. 16-26, 2015.
DOI | Google Scholar
41
-
X. Xu, M. Han, T. Li, et al., “Effective treatment of severe COVID-19 patients with tocilizumab,” Proc Natl Acad Sci USA, vol. 117, no. 20, pp. 10970-10975, 2020.
DOI | Google Scholar
42
-
Indian Ministry of Health and Family Welfare (2020). Clinical Management Protocol for COVID 19 [Online]. Available from: https://www.mohfw.gov.in/.
Google Scholar
43
-
U. Hamiel, E. Kozer, I. Youngster, “SARS-CoV-2 rates in BCG-vaccinated and unvaccinated young adults,” JAMA, vol. 323, no. 22, pp. 2340-2341 2020.
DOI | Google Scholar
44
-
C.H. Weng, A. Saal A, W.W. Butt, “Bacillus Calmette-Guérin vaccination and clinical characteristics and outcomes of COVID-19 in Rhode Island, United States: a cohort study,” Epidemiol Infect, pp. 1-9, 2020.
DOI | Google Scholar
45
-
L.E. Escobar, A. Molina-Cruz, C. Barillas-Mury, “BCG vaccine protection from severe coronavirus,” PNAS Appl Biol Sci, pp. 1-7, 2020.
DOI | Google Scholar
46
-
P.F. Cespedes, E.R. Jurado, J.A. Ezpinoza, et al., “A single, low dose of cGMP recombinant BCG vaccine elicit protective T cell immunity against the human respiratory syncytial virus infection and prevents lung pathology in mice,” Vaccine vol. 35, no. 5, pp. 757-76, 2017.
DOI | Google Scholar
47